Skip to main content
. Author manuscript; available in PMC: 2010 Apr 6.
Published in final edited form as: J Immunol. 2008 Nov 15;181(10):6797–6802. doi: 10.4049/jimmunol.181.10.6797

FIGURE 5.

FIGURE 5

Inhibition of GSK3 augments the systemic levels of IFN-β by mice given LPS. Intraperitoneal administration of the GSK3 inhibitor SB216763 (10 μg/g) significantly increased the levels of IFN-β by mice given 5 μg/g of LPS. Results represent the mean ± SD of five mice/group. In vivo levels of IFN-β in plasma were measured by ELISA 6 h after mice were given LPS. Sham-immunized mice were given PBS containing 0.1% DMSO. *, Statistically significant differences at p < 0.05 compared with control mice given LPS containing 0.1% DMSO. All groups of mice were given PBS containing 0.1% DMSO with or without LPS or SB216763.